Isocitrate Dehydrogenase-1 (IDH1) is an enzyme that plays a crucial role in cellular metabolism. It is involved in the citric acid cycle, which is essential for energy production in cells. The enzyme is NADP(+)-dependent and is found in the cytoplasm and peroxisomes of cells. IDH1 is known for its role in catalyzing the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, producing NADPH in the process.
IDH1 functions as a homodimer and is highly conserved across different species. The enzyme’s activity is critical for maintaining cellular redox balance and providing NADPH for biosynthetic processes and antioxidant defense. Mutations in IDH1, particularly the R132H mutation, have been implicated in various cancers, including gliomas and acute myeloid leukemia (AML). These mutations result in a neomorphic enzyme activity that produces 2-hydroxyglutarate (2-HG), an oncometabolite that contributes to tumorigenesis.
The Mouse Anti-Human IDH1 antibody is a monoclonal antibody that specifically recognizes both wild-type and mutant forms of IDH1. This antibody is commonly used in research to study the expression and function of IDH1 in various biological contexts. It is particularly useful in techniques such as flow cytometry, Western blotting, immunohistochemistry, and immunocytochemistry.
The study of IDH1 and its mutations is of great importance in cancer research. The R132H mutation, in particular, is a common alteration in gliomas and AML. The Mouse Anti-Human IDH1 antibody is a valuable tool for detecting this mutation and studying its effects on cellular metabolism and tumorigenesis. By understanding the role of IDH1 mutations, researchers can develop targeted therapies to inhibit the production of 2-HG and potentially treat cancers associated with these mutations.